In order to test this hypothesis that EMP-PDI plays a key role in promoting platelet activation in diabetes, we tested the activation of platelets, the amounts of MPs, PMPs, and EMPs, as well as concentration and activity of PDI, in patients with diabetic CHD and non-diabetic CHD, and confirmed the role of PDI in platelet activation in vitro. Here, MAEA is linked to coronary artery disorder.